Managing the complexities of cardiac amyloidosis: a path for success

Glener GC . Amyloid deposits and amyloidosis: the beta-fibrilloses. N Engl J Med 1980; 302: 1283–1292.

Kyle RA Bayrd ED. Amyloidosis: review of 236 cases. Medicine 1975; 54: 271–299.

Barrett CD Dobos K Liedtke M , et al. A changing landscape of mortality for systemic light chain amyloidosis. J Am Coll Cardiol HF 2019; 7: 958–966.

Adams D Gonzalez-Duarte A O’Riordan WD , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11–21.

Benson MD Waddington-Cruz M Berk JL , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 22–31.

Mauer MS Schwartz JH Gundapaneni B , et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379: 1007–1016.

Wechalekar AD Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J 2017; 7: e546.

Witteles RM Bokhari S Damy T , et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. J Am Coll Cardiol HF 2019; 7: 709–716.

Falk RH Quarta CC Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging 2014; 7: 552–562.

Aimo A Rapezzi C Vergaro G , et al. Management of complications of cardiac amyloidosis: ten questions and answers. Eur J Prev Cardiol 2020, epub ahead of point, DOI: 10.1177/2047487320920756.

Virchow R. Der Mensch (On Man). Berlin, 1849. English translation in Rather LJ, Disease, Life and Man – Selected Essays of Rudolf Virchow. Stanford, CA: Stanford University Press, 1958, pp. 67–70.